Ozempic, Wegovy and other GLP-1 drugs have been shown to curb alcohol effects, a new study suggests. Glucagon-like peptide-1 ...

More information on the Phase 1 study can be found at www.clinicaltrials.gov, identifier NCT06036784. About MBX 1416 MBX 1416 is an investigational long-acting glucagon-like peptide-1 (GLP-1) receptor ...

In the international SUMMIT trial, adults with heart failure preserved ejection fraction (HFpEF) and obesity taking tirzepatide for up to 3 years had a reduced combined risk of worsening heart failure ...

GLP-1 drug shortages, driven by cosmetic and weight loss purposes, result in access disparities among individuals with ...

SUMMT has shown for the first time that a drug can reduce major heart failure clinical outcomes in patients with heart ...

In addition to ensuring equitable access to the glucagon-like peptide-1 (GLP-1) receptor agonists, the medical community ...

Long-acting pharmacotherapies targeting incretin hormones like glucagon-like peptide-1 (GLP-1) and glucose-dependent ...

Payers and employers have tightened access to the glucagon-like peptide-1 receptor agonist class once these therapies became ...

On October 3, Amy Kane, 35, who once weighed 300 pounds at her heaviest, garnered 1.7 million views (@amyinhalf) after ...

About The Article: This Viewpoint discusses the health benefits of glucagon-like peptide-1 receptor agonists (GLP-1 RAs); summarizes the clinical, policy, and equity implications of GLP-1 RA ...

Garrett H. Garner, MD, Medical Director at SimpleFixRx to review it all for accuracy. Dr, Garner said, "Glucagon-like peptide ...

Metsera has brought in over $500m in funding in just seven months as it looks to enter the competitive weight loss arena.